{"pmid":32323577,"title":"What the oncologist needs to know about COVID-19 infection in cancer patients.","text":["What the oncologist needs to know about COVID-19 infection in cancer patients.","Future Oncol","Rassy, Elie","Khoury-Abboud, Rita-Maria","Ibrahim, Nathalie","Kattan, Clarisse","Assi, Tarek","Kattan, Joseph","32323577"],"journal":"Future Oncol","authors":["Rassy, Elie","Khoury-Abboud, Rita-Maria","Ibrahim, Nathalie","Kattan, Clarisse","Assi, Tarek","Kattan, Joseph"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323577","week":"202017|Apr 20 - Apr 26","doi":"10.2217/fon-2020-0312","keywords":["covid-19","chemotherapy","coronavirus","immune checkpoint inhibitors","oncologist","oncology","review"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664895932692430848,"score":8.518259,"similar":[{"pmid":32247204,"pmcid":"PMC7138158","title":"The impact of Coronavirus (COVID-19) on head and neck cancer patients' care.","text":["The impact of Coronavirus (COVID-19) on head and neck cancer patients' care.","Radiother Oncol","De Felice, Francesca","Polimeni, Antonella","Valentini, Vincenzo","32247204"],"journal":"Radiother Oncol","authors":["De Felice, Francesca","Polimeni, Antonella","Valentini, Vincenzo"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247204","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.radonc.2020.03.020","keywords":["covid-19","care","chemotherapy","coronavirus","head neck cancer","radiotherapy","surgery","treatment"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664638040137531392,"score":85.789925},{"pmid":32072569,"title":"2019 Novel coronavirus: where we are and what we know.","text":["2019 Novel coronavirus: where we are and what we know.","There is a current worldwide outbreak of a new type of coronavirus (2019-nCoV), which originated from Wuhan in China and has now spread to 17 other countries. Governments are under increased pressure to stop the outbreak spiraling into a global health emergency. At this stage, preparedness, transparency, and sharing of information are crucial to risk assessments and beginning outbreak control activities. This information should include reports from outbreak sites and from laboratories supporting the investigation. This paper aggregates and consolidates the virology, epidemiology, clinical management strategies from both English and Chinese literature, official news channels, and other official government documents. In addition, by fitting the number of infections with a single-term exponential model, we report that the infection is spreading at an exponential rate, with a doubling period of 1.8 days.","Infection","Cheng, Zhangkai J","Shan, Jing","32072569"],"abstract":["There is a current worldwide outbreak of a new type of coronavirus (2019-nCoV), which originated from Wuhan in China and has now spread to 17 other countries. Governments are under increased pressure to stop the outbreak spiraling into a global health emergency. At this stage, preparedness, transparency, and sharing of information are crucial to risk assessments and beginning outbreak control activities. This information should include reports from outbreak sites and from laboratories supporting the investigation. This paper aggregates and consolidates the virology, epidemiology, clinical management strategies from both English and Chinese literature, official news channels, and other official government documents. In addition, by fitting the number of infections with a single-term exponential model, we report that the infection is spreading at an exponential rate, with a doubling period of 1.8 days."],"journal":"Infection","authors":["Cheng, Zhangkai J","Shan, Jing"],"date":"2020-02-20T11:00:00Z","year":2020,"_id":"32072569","week":"20208|Feb 17 - Feb 23","doi":"10.1007/s15010-020-01401-y","keywords":["2019-ncov","covid-19","china","clinical guideline","coronavirus","epidemiology","literature review","literature survey","novel coronavirus","review","virology","wuhan"],"source":"PubMed","topics":["Mechanism","Epidemic Forecasting","Treatment","Transmission"],"weight":1,"locations":["Wuhan","China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875255300098,"score":82.439186},{"pmid":32311643,"title":"Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey.","text":["Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey.","The novel severe acute respiratory syndrome coronavirus-2 pandemic is a global health problem, which started to affect China by the end of 2019. In Europe, Italy has faced this novel disease entity (named novel coronavirus disease [COVID-19]) first and severely. COVID-19 represents a significant hurdle for public health services and a potential harm for patients with cancer. The Collegio Italiano dei Primari Oncologi Medici (CIPOMO) is an Italian association of head physicians in oncology departments, which promotes working and research activities in oncology on a national basis. In the midst of the epidemic in Italy, the CIPOMO promoted a national survey aiming to evaluate the impact of COVID-19 on clinical activity of oncologists and the implementation of containment measures of COVID-19 diffusion. Overall, 122 head physicians participated in this survey, with a homogeneous distribution on the national territory. Results show that the following measures for oncologic patients have been promptly implemented through the whole country: use of protective devices, triage of patients accessing the hospital, delay of non-urgent visits and use of telemedicine. Results of this survey suggest that Italian oncology departments have promptly set a proactive approach to the actual emergency. Oncologists need to preserve the continuum of care of patients, as the benefit of ensuring a well-delivered anti-cancer treatment plan outweighs the risk of COVID-19 infection. International cooperation is an important starting point, as heavily affected nations can serve as an example to find out ways to safely preserve health activity during the pandemic.","Eur J Cancer","Indini, Alice","Aschele, Carlo","Cavanna, Luigi","Clerico, Mario","Daniele, Bruno","Fiorentini, Giammaria","Fioretto, Luisa","Giordano, Monica","Montesarchio, Vincenzo","Ortega, Cinzia","Pinotti, Graziella","Scanni, Alberto","Zamagni, Claudio","Blasi, Livio","Grossi, Francesco","32311643"],"abstract":["The novel severe acute respiratory syndrome coronavirus-2 pandemic is a global health problem, which started to affect China by the end of 2019. In Europe, Italy has faced this novel disease entity (named novel coronavirus disease [COVID-19]) first and severely. COVID-19 represents a significant hurdle for public health services and a potential harm for patients with cancer. The Collegio Italiano dei Primari Oncologi Medici (CIPOMO) is an Italian association of head physicians in oncology departments, which promotes working and research activities in oncology on a national basis. In the midst of the epidemic in Italy, the CIPOMO promoted a national survey aiming to evaluate the impact of COVID-19 on clinical activity of oncologists and the implementation of containment measures of COVID-19 diffusion. Overall, 122 head physicians participated in this survey, with a homogeneous distribution on the national territory. Results show that the following measures for oncologic patients have been promptly implemented through the whole country: use of protective devices, triage of patients accessing the hospital, delay of non-urgent visits and use of telemedicine. Results of this survey suggest that Italian oncology departments have promptly set a proactive approach to the actual emergency. Oncologists need to preserve the continuum of care of patients, as the benefit of ensuring a well-delivered anti-cancer treatment plan outweighs the risk of COVID-19 infection. International cooperation is an important starting point, as heavily affected nations can serve as an example to find out ways to safely preserve health activity during the pandemic."],"journal":"Eur J Cancer","authors":["Indini, Alice","Aschele, Carlo","Cavanna, Luigi","Clerico, Mario","Daniele, Bruno","Fiorentini, Giammaria","Fioretto, Luisa","Giordano, Monica","Montesarchio, Vincenzo","Ortega, Cinzia","Pinotti, Graziella","Scanni, Alberto","Zamagni, Claudio","Blasi, Livio","Grossi, Francesco"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311643","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ejca.2020.03.024","keywords":["cancer","coronavirus","health care","infection","oncology","pandemic"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["China","Italy","Italian","Italy","Italian","Italian"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"_version_":1664632501417541634,"score":81.40468},{"pmid":32237263,"title":"Treatment approach in locally advanced rectal cancer during Coronavirus (COVID-19) pandemic: long course or short course?","text":["Treatment approach in locally advanced rectal cancer during Coronavirus (COVID-19) pandemic: long course or short course?","In this document, we briefly share the strategies and actions for patients with locally advanced rectal cancer to face the challenges of Coronavirus disease 2019 (COVID-19).","Colorectal Dis","De Felice, F","Petrucciani, N","32237263"],"abstract":["In this document, we briefly share the strategies and actions for patients with locally advanced rectal cancer to face the challenges of Coronavirus disease 2019 (COVID-19)."],"journal":"Colorectal Dis","authors":["De Felice, F","Petrucciani, N"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237263","week":"202014|Mar 30 - Apr 05","doi":"10.1111/codi.15058","keywords":["covid-19","chemotherapy","coronavirus","radiotherapy","rectal cancer","surgery","treatment"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638354162974721,"score":73.59958},{"pmid":32212881,"pmcid":"PMC7117596","title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","text":["Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","Immunotherapy","Bersanelli, Melissa","32212881"],"journal":"Immunotherapy","authors":["Bersanelli, Melissa"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32212881","week":"202013|Mar 23 - Mar 29","doi":"10.2217/imt-2020-0067","keywords":["anti-ctla-4","covid-19","sars-cov-2","anti-pd-1","anti-pd-l1","cancer patients","immune checkpoint inhibitors","immunotherapy","tocilizumab","viral infection"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664638838302048258,"score":72.916115}]}